Influenza Vaccination Rates Among Patients With a History of Cancer: Analysis of the National Health Interview Survey

Overview

Journal Open Forum Infect Dis

Specialty Infectious Diseases

Date 2021 Jul 29

PMID 34322565

Citations 7

Authors

Andres Chang

Mallory K Ellingson

Christopher R Flowers

Robert A Bednarczyk

Affiliations

Soon will be listed here.

Abstract

Background: Annual influenza vaccination is recommended for all patients with cancer, but vaccine uptake data by cancer type and time since diagnosis are limited. We sought to estimate vaccination rates across different cancer types in the United States and determine whether rates vary over time since diagnosis.

Methods: Vaccination rates in individuals with solid tumor and hematological malignancies were estimated using data from 59 917 individuals obtained by the 2016 and 2017 National Health Interview Survey conducted by the Centers for Disease Control and Prevention.

Results: An average of 64% of the 5053 individuals with self-reported cancer received the influenza vaccine. Vaccination rates in men and women with solid tumors (66.6% and 60.3%, respectively) and hematological malignancies (58.1% and 59.2%, respectively) were significantly higher compared to those without cancer (38.9% and 46.8%, respectively). Lower rates were seen in uninsured patients, those younger than 45 years of age, and in African Americans with hematological malignancies but not with solid tumors. Vaccine uptake was similar regardless of time since cancer diagnosis.

Conclusions: Influenza vaccination rates are higher in men and women with cancer but remain suboptimal, highlighting the need for additional measures to improve vaccine compliance and prevent complications from influenza across all cancer types.

Citing Articles

Immune Checkpoint Inhibitors and Vaccination: Assessing Safety, Efficacy, and Synergistic Potential.

New J, Shenton L, Ksayer R, Wang J, Zakharia K, Nicholson L Vaccines (Basel). 2024; 12(11).

PMID: 39591173 PMC: 11598700. DOI: 10.3390/vaccines12111270.

Streptococcus pneumoniae and influenza vaccination rates in oncological patients - data from Germany.

Niederstein E, Underwood J, de Wit M, Reinwald M, Schwarzlose-Schwarck S, Dammermann W Support Care Cancer. 2024; 32(12):813.

PMID: 39570461 PMC: 11582192. DOI: 10.1007/s00520-024-09023-y.

Disparities with influenza vaccine use in long-term survivors of metastatic breast cancer.

Doshi S, DeStephano D, Accordino M, Elkin E, Raghunathan R, Wright J Breast Cancer Res Treat. 2023; 203(1):111-119.

PMID: 37688666 DOI: 10.1007/s10549-023-07109-5.

Preventive health care in blood cancer survivors: results from the ABC study.

Baum J, Lax H, Lehmann N, Merkel-Jens A, Beelen D, Jockel K J Cancer Res Clin Oncol. 2023; 149(13):11531-11540.

PMID: 37395845 PMC: 10465397. DOI: 10.1007/s00432-023-04984-9.

Individual-level factors associated with COVID-19 vaccine acceptance among U.S. patients with cancer.

Hathaway C, Siegel E, Gonzalez B, Oswald L, Peoples A, Ulrich C Vaccine. 2022; 40(46):6649-6657.

PMID: 36210253 PMC: 9515327. DOI: 10.1016/j.vaccine.2022.09.063.

References

Marellapudi A, King A, Bednarczyk R . Presentation of caregiver-specific vaccine-related information on National Cancer Institute designated cancer center websites. Vaccine. 2020; 38(40):6248-6253. DOI: 10.1016/j.vaccine.2020.07.052. View

Cho A, Bradley B, Kauffman R, Priyamvada L, Kovalenkov Y, Feldman R . Robust memory responses against influenza vaccination in pemphigus patients previously treated with rituximab. JCI Insight. 2017; 2(12). PMC: 5470882. DOI: 10.1172/jci.insight.93222. View

Grohskopf L, Alyanak E, Broder K, Blanton L, Fry A, Jernigan D . Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices - United States, 2020-21 Influenza Season. MMWR Recomm Rep. 2020; 69(8):1-24. PMC: 7439976. DOI: 10.15585/mmwr.rr6908a1. View

Demicheli V, Jefferson T, Ferroni E, Rivetti A, Di Pietrantonj C . Vaccines for preventing influenza in healthy adults. Cochrane Database Syst Rev. 2018; 2:CD001269. PMC: 6491184. DOI: 10.1002/14651858.CD001269.pub6. View

Jacob V, Chattopadhyay S, Hopkins D, Morgan J, Pitan A, Clymer J . Increasing Coverage of Appropriate Vaccinations: A Community Guide Systematic Economic Review. Am J Prev Med. 2016; 50(6):797-808. PMC: 4896867. DOI: 10.1016/j.amepre.2015.11.003. View

Taplitz R, Kennedy E, Bow E, Crews J, Gleason C, Hawley D . Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018; 36(30):3043-3054. DOI: 10.1200/JCO.18.00374. View

Lu P, OHalloran A, Bryan L, Kennedy E, Ding H, Graitcer S . Trends in racial/ethnic disparities in influenza vaccination coverage among adults during the 2007-08 through 2011-12 seasons. Am J Infect Control. 2014; 42(7):763-9. PMC: 5822446. DOI: 10.1016/j.ajic.2014.03.021. View

Lu P, OHalloran A, Ding H, Srivastav A, Williams W . Uptake of Influenza Vaccination and Missed Opportunities Among Adults with High-Risk Conditions, United States, 2013. Am J Med. 2015; 129(6):636.e1-636.e11. PMC: 5831078. DOI: 10.1016/j.amjmed.2015.10.031. View

Tian C, Wang H, Wang W, Luo X . Characteristics associated with influenza vaccination uptake among adults. J Public Health (Oxf). 2018; 41(3):e267-e273. DOI: 10.1093/pubmed/fdy189. View

10.

Yri O, Torfoss D, Hungnes O, Tierens A, Waalen K, Nordoy T . Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011; 118(26):6769-71. DOI: 10.1182/blood-2011-08-372649. View

11.

Rubin L, Levin M, Ljungman P, Davies E, Avery R, Tomblyn M . 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):309-18. DOI: 10.1093/cid/cit816. View

12.

Okoli G, Lam O, Abdulwahid T, Neilson C, Mahmud S, Abou-Setta A . Seasonal influenza vaccination among cancer patients: A systematic review and meta-analysis of the determinants. Curr Probl Cancer. 2020; 45(2):100646. DOI: 10.1016/j.currproblcancer.2020.100646. View

13.

OHalloran A, Lu P, Williams W, Bridges C, Singleton J . Influenza Vaccination Coverage Among People With High-Risk Conditions in the U.S. Am J Prev Med. 2015; 50(1):e15-e26. PMC: 4770254. DOI: 10.1016/j.amepre.2015.06.008. View

14.

Kunisaki K, Janoff E . Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis. 2009; 9(8):493-504. PMC: 2775097. DOI: 10.1016/S1473-3099(09)70175-6. View

15.

Ward E, Flowers C, Gansler T, Omer S, Bednarczyk R . The importance of immunization in cancer prevention, treatment, and survivorship. CA Cancer J Clin. 2017; 67(5):398-410. DOI: 10.3322/caac.21407. View

16.

Miller K, Siegel R, Lin C, Mariotto A, Kramer J, Rowland J . Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 2016; 66(4):271-89. DOI: 10.3322/caac.21349. View

17.

Shih Y, Pan I . Influenza vaccination among individuals with cancer and their family members. Am J Prev Med. 2010; 38(1):61-9. DOI: 10.1016/j.amepre.2009.09.032. View

18.

Bednarczyk R, Chamberlain A, Mathewson K, Salmon D, Omer S . Practice-, Provider-, and Patient-level interventions to improve preventive care: Development of the P3 Model. Prev Med Rep. 2018; 11:131-138. PMC: 6040109. DOI: 10.1016/j.pmedr.2018.06.009. View

19.

Locher J, Rucks A, Spencer S, Pettaway G, Kilgore M . Influenza immunization in older adults with and without cancer. J Am Geriatr Soc. 2012; 60(11):2099-103. DOI: 10.1111/j.1532-5415.2012.04196.x. View

20.

Baden L, Swaminathan S, Angarone M, Blouin G, Camins B, Casper C . Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016; 14(7):882-913. DOI: 10.6004/jnccn.2016.0093. View